Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites
A Clinical Study to Evaluate the Safety and Efficacy on Veloderm (a Crystalline Cellulose Simple Occlusive Dressing) for the Split-thickness Skin Graft Donor Sites in Burn and Plastic Surgery
Sponsor: Guangzhou First People's Hospital
Listed as NCT01512017, this PHASE3 trial focuses on Split-thickness Skin Graft Donor Sites and remains completed. Sponsored by Guangzhou First People's Hospital, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2017 [monthly]
Completed PHASE3
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangzhou First People's Hospital
- Lee's Pharmaceutical Limited
- Ruijin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.